Navigation Links
Halozyme Reports First Quarter 2013 Financial Results
Date:5/8/2013

SAN DIEGO, May 8, 2013 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) today reported financial results for the quarter ended March 31, 2013.

(Logo: http://photos.prnewswire.com/prnh/20100302/LA63139LOGO)

"With the potential for 3 new product launches over the next 12 months and continued progress on the Hylenex® brand, I am pleased with the steps we are making towards our near term revenue drivers," said Gregory I. Frost , Ph.D., President and Chief Executive Officer, Halozyme. "Moreover, over the next 8 weeks, we will present a first-look at clinical data from our innovative pipeline products, PEGPH20 and HTI-501."

Highlights of Halozyme's first quarter activities and recent events include:

  • The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) granted a positive opinion to Baxter for the use of HyQvia as replacement therapy for adult patients with primary and secondary immunodeficiencies.
  • Initiated a 124 patient Phase 2 clinical study evaluating PEGPH20, a proprietary, investigational drug, as a first-line therapy for patients with stage IV metastatic pancreatic cancer. Patients in the study will receive gemcitabine and nab-paclitaxel either with or without PEGPH20. The primary endpoint will be to measure progression-free survival.
  • Initiated a 400 patient Phase 4 clinical study – The CONtinuous Subcutaneous Insulin infusion STudy ENrolling Type 1 Diabetes (CONSISTENT 1) – that will evaluate Hylenex use in conjunction with rapid analog insulin in people with Type 1 diabetes using insulin pumps. The primary endpoints include metabolic and safety outcomes.
  • Investigators at Yale received FDA clearance to start an artificial pancreas investigator initiated trial that incorporates Hylenex.  The study will test the effect of Hylenex in the continuous loop setting.
  • Initiated an additional multi-lot campaign with our higher productivity manufacturing process to support potential Roche product launches.
  • Appointed Matt Posard , Senior Vice President and General Manager of Translational & Consumer Genomics at Illumina, Inc., to our Board of Directors.
  • First Quarter 2013 Financial Highlights

  • Revenues for the first quarter of 2013 were $11.8 million, compared to $7.4 million for the first quarter of 2012. Revenues in the first quarter of 2013 included $9.7 million in revenue from research and development reimbursements from partners primarily related to manufacturing activities to support potential launches by our partners.
  • Research and development expenses for the first quarter of 2013 were $22.0 million, compared with $15.9 million for the first quarter of 2012. The increase was due primarily to an increase in manufacturing activities to support potential launches by our partners and an increase in clinical trial activities.
  • Selling, general and administrative expenses for the first quarter of 2013 were $7.6 million, compared to $6.6 million for the first quarter of 2012. The increase was mainly due to an increase in marketing activities.
  • The net loss for the first quarter of 2013 was $19.3 million, or $0.17 per share, compared with a net loss for the first quarter of 2012 of $15.1 million, or $0.14 per share.
  • Cash, cash equivalents and marketable securities were $87.4 million at March 31, 2013, compared with $99.5 million at December 31, 2012. Net cash used in the first quarter of 2013 was approximately $12.0 million.
  • Conference CallHalozyme will webcast its Quarterly Update Conference Call today at 4:30 p.m. ET/1:30 p.m. PT. Gregory I. Frost , Ph.D., Halozyme's President and Chief Executive Officer, will lead the call. During the call, the Company plans to provide further details underlying its first quarter 2013 financial results. The call will be webcast through the "Investors" section of Halozyme's corporate website at www.halozyme.com, and the recording will be made available for 90 days following the event. To access the live webcast, please log on to Halozyme's website approximately fifteen minutes prior to the presentation to register and download any necessary audio software. For those without access to the Internet, the live call may be accessed by phone by calling (877) 407-8037 (domestic callers) or (201) 689-8037 (international callers). A telephone replay will be available shortly after the call by dialing (877) 660-6853 (domestic callers) or (201) 612-7415 (international callers) using replay ID number 413625.

    Upcoming Conferences

  • Bank of America Merrill Lynch 2013 Healthcare Conference, Las Vegas, Nevada – 5/14
  • UBS Global Health Care Conference, New York, NY – 5/22
  • About HalozymeHalozyme Therapeutics is a biopharmaceutical company dedicated to developing and commercializing innovative products that advance patient care. With a diversified portfolio of enzymes that target the extracellular matrix, the Company's research focuses primarily on a family of human enzymes, known as hyaluronidases, which increase the absorption and dispersion of biologics, drugs and fluids. Halozyme's pipeline addresses therapeutic areas, including diabetes, oncology and dermatology that have significant unmet medical need. The Company markets Hylenex® recombinant (hyaluronidase human injection) and has partnerships with Roche, Pfizer, Baxter, ViroPharma and Intrexon. Halozyme is headquartered in San Diego, CA. For more information on how we are innovating, please visit our corporate website at www.halozyme.com.

    Safe Harbor Statement In addition to historical information, the statements set forth above include forward-looking statements (including, without limitation, statements concerning potential product launches and near-term revenue opportunities, the Company's expected presentation of data from the PEGPH20 Phase 1b study in pancreatic cancer and Phase 2 HTI-501 trial in cellulite, the development and commercialization of product candidates and the potential benefits and attributes of such product candidates) that involve risk and uncertainties that could cause actual results to differ materially from those in the forward-looking statements. The forward-looking statements are typically, but not always, identified through use of the words "believe," "enable," "may," "will," "could," "intends," "estimate," "anticipate," "plan," "predict," "probable," "potential," "possible," "should," "continue," and other words of similar meaning. Actual results could differ materially from the expectations contained in forward-looking statements as a result of several factors, including unexpected expenditures and costs, unexpected results or delays in development and regulatory review, regulatory approval requirements, unexpected adverse events and competitive conditions. These and other factors that may result in differences are discussed in greater detail in the Company's Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 1, 2013.Halozyme Therapeutics, Inc. Condensed Consolidated Statements of Operations(Unaudited)Three Months Ended March 31,20132012REVENUES:Product sales, net

    $
    ,508,594$
    87,411Revenues under collaborative agreements

    10,324,9467,252,768Total revenues

    11,833,5407,440,179OPERATING EXPENSES:Cost of product sales

    738,97170,761Research and development

    22,034,43715,891,109Selling, general and administrative

    7,555,9056,618,707Total operating expenses

    30,329,31322,580,577OPERATING LOSS

    (18,495,773)(15,140,398)Investment and other income

    54,98821,217Interest expense

    (847,584)-NET LOSS

    $ (19,288,369)$ (15,119,181)Basic and diluted net loss per share

    $
    (0.17)$
    (0.14)Shares used in computing basic and diluted

    net loss per share

    112,416,792107,589,514 Halozyme Therapeutics, Inc.Condensed Consolidated Balance Sheets(Unaudited)March 31,December 31,20132012ASSETSCurrent assets:Cash and cash equivalents

    $   39,017,804$   99,501,264Marketable securities, available-for-sale

    48,408,220-Accounts receivable, net

    10,375,73315,703,087Inventories

    2,737,3872,670,696Prepaid expenses and other assets

    10,571,33412,752,888Total current assets

    111,110,478130,627,935Property and equipment, net

    3,975,0523,700,462Prepaid expenses and other assets

    1,280,765-Restricted cash

    500,000400,000Total Assets

    $ 116,866,295$ 134,728,397LIABILITIES AND STOCKHOLDERS' EQUITYCurrent liabilities:Accounts payable 

    $
    2,884,794$
    2,271,689Accrued expenses

    9,177,5747,783,447Deferred revenue, current portion

    6,326,1588,891,017Current portion of long-term debt

    1,362,055-Total current liabilities

    19,750,58118,946,153Deferred revenue, net of current portion

    34,318,48134,954,966Long-term debt, net

    28,323,23329,661,680Lease financing obligation

    1,450,0001,450,000Deferred rent, net of current portion

    906,091861,879Other long term liability

    436,849-Stockholders' equity:Common stock

    113,143112,709Additional paid-in capital

    349,459,065347,314,658Accumulated other comprehensive loss

    (29,131)-Accumulated deficit

    (317,862,017)(298,573,648)Total stockholders' equity

    31,681,06048,853,719Total Liabilities and Stockholders' Equity

    $ 116,866,295$ 134,728,397 

    Investor Contact:
    Kurt Gustafson
    Halozyme Therapeutics
    858-704-8272
    ir@halozyme.com

    Media Contact:
    Nurha Hindi
    Hill + Knowlton Strategies
    310-633-9434
    Nurha.Hindi@hkstrategies.com


    '/>"/>
    SOURCE Halozyme Therapeutics, Inc.
    Copyright©2012 PR Newswire.
    All rights reserved

    Related medicine technology :

    1. Halozyme to Host First Quarter 2012 Financial Results Conference Call
    2. Halozyme Reports First Quarter 2012 Financial Results
    3. Halozyme Therapeutics to Present at the Jefferies 2012 Global Healthcare Conference
    4. Halozymes Ultrafast Insulin Formulations Improved Postprandial Glycemic Control in Patients Living with Type 1 Diabetes: Phase 2 Study Results Presented at ADA 2012
    5. Halozyme Confirms Baxter Has Received A Complete Response Letter For HyQ BLA
    6. Halozyme Reports Second Quarter 2012 Financial Results
    7. Halozyme to Host Third Quarter Financial Results Conference Call
    8. Halozyme Therapeutics To Present At The Lazard Capital Markets 9th Annual Healthcare Conference
    9. Halozyme Announced Roche Filed A Marketing Authorization Application For Subcutaneous MabThera
    10. Halozyme Reports Fourth Quarter and Year End 2012 Financial Results
    11. Halozyme Therapeutics to Present at the Barclays 2013 Global Healthcare Conference
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:6/23/2016)... June 23, 2016 Research and ... Excipients Market by Type (Organic Chemical (Sugar, Petrochemical, Glycerin), ... Topical, Coating, Parenteral) - Global Forecast to 2021" ... The global pharmaceutical excipients market is projected ... CAGR of 6.1% in the forecast period 2016 to ...
    (Date:6/23/2016)... 23, 2016 Roche (SIX: RO, ROG; OTCQX: ... its Elecsys BRAHMS PCT (procalcitonin) assay as a dedicated ... shock. With this clearance, Roche is the first IVD ... solution for sepsis risk assessment and management. ... and PCT levels in blood can aid clinicians in ...
    (Date:6/23/2016)... ANGELES , June 23, 2016 ... CAPR ), a biotechnology company focused ... therapeutics, today announced that patient enrollment in its ... in Duchenne) has exceeded 50% of its 24-patient ... enrollment in the third quarter of 2016, and ...
    Breaking Medicine Technology:
    (Date:6/27/2016)... Overland Park, KS (PRWEB) , ... June 27, 2016 , ... ... leader in retailers of Eyeglasses . , Millions of individuals in the United ... life, eyeglasses have become a way to both correct vision and make a fashion ...
    (Date:6/26/2016)... , ... June 26, 2016 , ... PawPaws brand ... new product that was developed to enhance the health of felines. The formula is ... The two main herbs in the PawPaws Cat Kidney Support Supplement Soft ...
    (Date:6/25/2016)... ... , ... Austin residents seeking Mohs surgery services, can now turn to Dr. ... Russell Peckham for medical and surgical dermatology. , Dr. Dorsey brings specialization to include ... in Mohs Micrographic Surgery completed by Dr. Dorsey was under the direction of Glenn ...
    (Date:6/25/2016)... , ... June 25, 2016 , ... As a lifelong ... Cum Laude and his M.D from the David Geffen School of Medicine at UCLA. ... to Los Angeles to complete his fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai ...
    (Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... A recent ... that most people are unfamiliar with. The article goes on to state that individuals ... also many of these less common operations such as calf and cheek reduction. The ...
    Breaking Medicine News(10 mins):